Bedrijfsoverzicht
OraSure Technologies, Inc. is a specialized entity within the healthcare sector that focuses on the development, manufacturing, and distribution of diagnostic products and specimen collection devices across the United States, Europe, Africa, and international markets. The company primarily operates in the medical instruments and supplies industry, providing critical tools such as the OraQuick Rapid HIV test and self-testing kits to healthcare providers and consumers globally. This organization employs approximately 500 individuals and holds a market capitalization of $204.61M, reflecting its status as a mid-cap player in the broader healthcare landscape. The annual revenue generated over the trailing twelve months stands at $115.02M, a figure that contextualizes the company's scale as a significant but not dominant force within the niche of point-of-care diagnostics, indicating a specialized market position rather than mass-market dominance.
Financiële gezondheid
The financial performance of OraSure Technologies, Inc. over the trailing twelve months reveals a revenue stream of $115.02M, which contrasts sharply with a net income of -$68,731,000 and an EBITDA of -$57,432,000. The substantial gap between the reported revenue and the significant net loss highlights a challenging cost structure where operating expenses and losses significantly erode gross profitability, resulting in a profit margin of -59.8%. Furthermore, the operating margin stands at -61.1%, while the gross margin is reported at 41.9%, indicating that while the core products maintain pricing power or cost efficiency, the overall operational overheads are currently unsustainable. The company reports a free cash flow of -$17,041,000, which suggests limited financial flexibility as the business is currently burning cash rather than generating liquidity for expansion or shareholder returns. On the balance sheet, OraSure holds $199.28M in cash against $13.20M in debt, creating a robust net cash position that provides a safety buffer despite the negative earnings. The debt-to-equity ratio is recorded at 3.87, yet the absolute leverage is mitigated by the significant cash reserves, presenting a complex picture of a leveraged entity with strong liquidity. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 6.58, which indicates the company possesses more than six times the current assets necessary to cover its current liabilities. Regarding return metrics, the return on equity is -18.3% and the return on assets is -9.6%, revealing that management is currently unable to generate positive returns on the capital deployed, which points to operational inefficiencies or strategic investments that have not yet yielded financial rewards.
Waarderingsbeoordeling
Valuation metrics for OraSure Technologies, Inc. present a mixed picture due to the company's profitability status, with a trailing P/E ratio marked as N/A and a forward P/E of -6.30. The absence of a trailing P/E ratio is a direct consequence of the negative net income, while the negative forward P/E implies that analysts are not pricing in an immediate earnings recovery to positive levels in the short term. The price-to-book ratio is 0.61, indicating that the market values the company at approximately 39% below its tangible book value, which often suggests a deep discount or market skepticism regarding future earnings potential. Alternative valuation multiples provide further insight, with a price-to-sales ratio of 1.78 and an EV/EBITDA of -0.32, suggesting that the stock is priced relative to sales rather than earnings, a common approach for unprofitable biotech or medical device firms. The stock has traded within a 52-week range with a high of $3.82 and a low of $2.08; without a specific current price in the provided facts to calculate a percentage, the valuation range is bounded strictly by these historical extremes. The beta value is 0.85, which indicates that the stock's price volatility is slightly lower than the broader market benchmark, suggesting it may be slightly less sensitive to general market swings than the average equity.
Growth & Income
Growth dynamics for OraSure Technologies, Inc. are currently characterized by contraction rather than expansion, with revenue growth year-over-year standing at -28.5%. Earnings growth is listed as N/A due to the lack of positive earnings data, making a direct comparison between earnings and revenue growth rates impossible under current conditions. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash is retained within the business or used to service debt and operational needs rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the early stages of recovery or those requiring capital to fund R&D and manufacturing improvements, although the current negative free cash flow complicates the sustainability of such growth initiatives. The overall profile of the company reflects a firm in a challenging growth phase, where the focus appears to be on stabilizing operations and reducing losses rather than delivering immediate income or top-line expansion.